502612-43-3

Basic information

• Product Name: 5-Isoquinolinamine,5,6,7,8-tetrahydro-(9CI)
• Synonyms: 5-Isoquinolinamine,5,6,7,8-tetrahydro-(9CI);5,6,7,8-tetrahydro-5-Isoquinolinamine
• CAS NO: 502612-43-3
• Molecular Formula: C₉H₁₂N₂
• Molecular Weight: 148.208
• Product Categories: PYRIDINE;AMINEPRIMARY
• Mol File: 502612-43-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 268.554 °C at 760 mmHg
• Flash Point: 140.374 °C
• Appearance: /
• Density: 1.081 g/cm³
• Vapor Pressure: 0.008mmHg at 25°C
• Refractive Index: 1.566
• CAS DataBase Reference: 5-Isoquinolinamine,5,6,7,8-tetrahydro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Isoquinolinamine,5,6,7,8-tetrahydro-(9CI)(502612-43-3)
• EPA Substance Registry System: 5-Isoquinolinamine,5,6,7,8-tetrahydro-(9CI)(502612-43-3)

Safety Data

• Hazardous Substances Data: 502612-43-3(Hazardous Substances Data)

Usage

General Description

5-Isoquinolinamine, 5,6,7,8-tetrahydro-(9CI) is a chemical compound with the molecular formula C9H11N. It is a derivative of isoquinoline, a heterocyclic compound consisting of a benzene ring fused to a pyridine ring. The presence of the tetrahydro group indicates that it has four hydrogen atoms added to the isoquinoline structure, resulting in a saturated ring system. 5-Isoquinolinamine,5,6,7,8-tetrahydro-(9CI) has potential applications in the pharmaceutical industry, particularly in the development of new drugs and therapeutic agents. Its specific biological and chemical properties make it a valuable target for further research and development.

InChI:InChI=1/C9H12N2/c10-9-3-1-2-7-6-11-5-4-8(7)9/h4-6,9H,1-3,10H2

Upstream product

• 36556-06-6 5,6,7,8-tetrahydroisoquinoline 
• 1374781-15-3 (Z)-7,8-dihydroisoquinolin-5(6H)-one oxime 
• 119-65-3 isoquinoline 
• 115787-46-7 7,8-dihydroisoquinolin-5(6H)-one oxime 

Downstream Products

• 697739-81-4 C₂₀H₁₆ClF₃N₄ 

Relevant articles and documents

SUBSTITUTED BICYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted bicyclic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions.

AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN

the present invention provides a compound of formula (I): wherein V represents NR5, O, S, SO or S(O)2; W and X each independently represent CH or N; Y represents N, CH or C-Ar2, with the proviso that at least one, but no more than two, of W, X and Y are N; Z represents CH or C-Ar2, with the proviso that when Y is N or CH then Z is C-Ar2, and with the further proviso that when Y is C-Ar2 then Z is CH; Ar1 represents a fused 9 or 10 membered heterobicyclic ring system containing one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, wherein at least one of the rings in said ring system is aromatic; Ar2 represents an aromatic ring selected from phenyl, pyridyl, pyrimidinyl and pyridazinyl which is optionally fused and substituted; R1 represents halogen, hydroxy, oxo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkoxy, C3-7cycloalkyl, C3-7cycloalkoxy, C3-5cycloalkylC1-4alkyl, cyano, nitro, SR6, SOR6, SO2R6, COR6, NR3COR6, CONR3R4, NR3SO2R6, SO2NR3R4, -(CH2)mcarboxy, esterified -(CH2)mcarboxy or -(CH2)mNR3R4; R2 represents hydrogen, halogen, hydroxy, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy, haloC1-6alkoxy, unsubstituted phenyl or phenyl substituted with one or two groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or haloC1-6alkoxy; R3 and R4 are each independently hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl or fluoroC1-6alkyl; or R3 and R4 and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C1-4alkoxy, which ring may optionally contain as one of the said ring atoms an oxygen or a sulfur atom, S(O), S(O)2, or NR5; R5 represents hydrogen, C1-4alkyl, hydroxyC1-4alkyl or C1-4alkoxyC1-4alkyl; R6 represents hydrogen, C1-6alkyl, fluoroC1-6alkyl, C3-7cycloalkyl, unsubstituted phenyl, or phenyl substituted with one or two groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or haloC1-6alkoxy; m is either zero or an integer from 1 to 4; n is either zero or an integer from 1 to 3; or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof; a pharmaceutical composition comprising it; its use in methods of treatment; use of it for the manufacture of a medicament for treating VR-1 related conditions such as those in which pain and/or inflammation predominate; and methods of treatment using it.